» Articles » PMID: 32080423

Mechanisms of Diabetic Cardiomyopathy and Potential Therapeutic Strategies: Preclinical and Clinical Evidence

Overview
Journal Nat Rev Cardiol
Date 2020 Feb 22
PMID 32080423
Citations 294
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied in the past decade, but effective approaches to prevent and treat this disease are limited. Diabetic cardiomyopathy occurs as a result of the dysregulated glucose and lipid metabolism associated with diabetes mellitus, which leads to increased oxidative stress and the activation of multiple inflammatory pathways that mediate cellular and extracellular injury, pathological cardiac remodelling, and diastolic and systolic dysfunction. Preclinical studies in animal models of diabetes have identified multiple intracellular pathways involved in the pathogenesis of diabetic cardiomyopathy and potential cardioprotective strategies to prevent and treat the disease, including antifibrotic agents, anti-inflammatory agents and antioxidants. Some of these interventions have been tested in clinical trials and have shown favourable initial results. In this Review, we discuss the mechanisms underlying the development of diabetic cardiomyopathy and heart failure in type 1 and type 2 diabetes mellitus, and we summarize the evidence from preclinical and clinical studies that might provide guidance for the development of targeted strategies. We also highlight some of the novel pharmacological therapeutic strategies for the treatment and prevention of diabetic cardiomyopathy.

Citing Articles

Echocardiographic Assessment in Various Obesity Phenotypes: A Cross-Sectional Study.

Sesha Satya Sagar V, Acharya S, Kumar S, Reddy H, Chavhan R, Reddy N Cureus. 2025; 17(2):e78716.

PMID: 40065855 PMC: 11891397. DOI: 10.7759/cureus.78716.


Downregulation of HSPB1 and MGST1 Promotes Ferroptosis and Impacts Immune Infiltration in Diabetic Cardiomyopathy.

Xie Y, Liang B, Meng Z, Guo R, Liu C, Yuan Y Cardiovasc Toxicol. 2025; .

PMID: 40053272 DOI: 10.1007/s12012-025-09982-6.


Therapeutic Targeting of Decr1 Ameliorates Cardiomyopathy by Suppressing Mitochondrial Fatty Acid Oxidation in Diabetic Mice.

Lu Q, Sun H, Zhou K, Su J, Meng X, Chen G J Cachexia Sarcopenia Muscle. 2025; 16(2):e13761.

PMID: 40052435 PMC: 11886612. DOI: 10.1002/jcsm.13761.


Novel impact of metal ion-induced cell death on diabetic cardiomyopathy pathogenesis and therapy.

Jiang J, Hu S, Hu K, Xiao L, Lin J, Chen Y Apoptosis. 2025; .

PMID: 40042744 DOI: 10.1007/s10495-025-02090-4.


L-arginine administration exacerbates myocardial injury in diabetics prooxidant and proinflammatory mechanisms along with myocardial structural disruption.

Mansouri R, Aboubakr E, Alshaibi H, Ahmed A World J Diabetes. 2025; 16(2):100395.

PMID: 39959273 PMC: 11718468. DOI: 10.4239/wjd.v16.i2.100395.


References
1.
Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu S . Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006; 113(4):544-54. DOI: 10.1161/CIRCULATIONAHA.105.537894. View

2.
Li Z, Wang Z, Yin Z, Zhang Y, Xue X, Han J . Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget. 2017; 8(32):53714-53729. PMC: 5581144. DOI: 10.18632/oncotarget.16342. View

3.
He X, Kan H, Cai L, Ma Q . Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol. 2008; 46(1):47-58. DOI: 10.1016/j.yjmcc.2008.10.007. View

4.
Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

5.
Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C . CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014; 129(21):2111-24. DOI: 10.1161/CIRCULATIONAHA.113.007101. View